Two key protein structures in the body are being visualized for the first time, thanks in part to the latest technology in ...

Poly (ADP-ribose) polymerase (PARP) inhibitors are used as maintenance therapy after completion of platinum-based chemotherapy in ovarian cancer. However, acquired or de novo resistance to PARP ...

From left to right: Dr. Jens Ruhe, Managing Director and Chief Operating Officer - Dr. Jan Poth, Managing Director and Chief Executive Officer - Dr. Matthias Schneider, Chief Scientific Officer ...

This multifaceted approach is aimed at preserving essential TACE/ADAM17-dependent functions. The therapy has the potential to modulate immune tolerance by enhancing TNFR2 signalling and regulatory ...

The rapid release of at least 80 signaling molecules, including tumor necrosis factor and epidermal growth factor, is controlled by a membrane-bound protease called ADAM17. This process involves ...

The findings cast iRhom2 as a new genetic modifier of sTREM2 release, and confirmed ADAM17 as a major TREM2 protease in microglia, Lichtenthaler concluded. He proposed that in addition to agonistic ...

We’ve also shown that CRISPR-mediated knockout of ADAM17, a suppressor of CD16 activity, can be used to further elevate ADCC, and to help maintain NK cell potency. These findings will be ...

There I discovered unexpected roles for the pseudoprotease iRhom2 in the regulation of the metalloprotease TACE/ADAM17, which triggers the release of the inflammatory cytokine, TNF, and many EGFR ...

Study: ADAM10 and ADAM17 promote SARS-CoV-2 cell entry and spike protein-mediated lung cell fusion. Image Credit: Design_Cells / Shutterstock Previous studies have revealed that S is a furin ...

We identify the host metalloprotease ADAM17 as a facilitator of SARS‐CoV‐2 cell entry and the metalloprotease ADAM10 as a host factor required for lung cell syncytia formation, a hallmark of COVID‐19 ...